YU11402A - Nova primena docetaksela za lečenje hepatoma - Google Patents

Nova primena docetaksela za lečenje hepatoma

Info

Publication number
YU11402A
YU11402A YU11402A YUP11402A YU11402A YU 11402 A YU11402 A YU 11402A YU 11402 A YU11402 A YU 11402A YU P11402 A YUP11402 A YU P11402A YU 11402 A YU11402 A YU 11402A
Authority
YU
Yugoslavia
Prior art keywords
docetaxel
new use
treating hepatoma
hepatoma
treating
Prior art date
Application number
YU11402A
Other languages
English (en)
Inventor
Chin-Wen Chi
Heng-Liang Lin
Tsung-Yun Liu
Wing-Yiu Lui
Gar-Yang Chau
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of YU11402A publication Critical patent/YU11402A/sh
Publication of RS50148B publication Critical patent/RS50148B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Ovaj pronalazak se zasniva na nalazu da je docetaksel znatno aktivniji protiv ćelija hepatoćelijskih karcinoma od paklitaksela pri koncentracijama do 1ВµM. Prema tome ovaj pronalazak daje primenu docetaksela ili njegovog hidrata u proizvodnji leka za primenu u lečenju hepatoćelijskog karcinoma.[The present invention is based on the finding that docetaxel is significantly more active against hepatocellular carcinoma cells than paclitaxel at concentrations of up to 1ВµM. It accordingly provides the use of docetaxel, or a hydrate thereof, in the manufacture of a medicament for use in the treatment of hepatocellular carcinoma.
YUP-114/02A 1999-08-31 2000-08-29 Upotreba docetaksela za lečenje hepatoćelijskog karcinoma RS50148B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
YU11402A true YU11402A (sh) 2005-07-19
RS50148B RS50148B (sr) 2009-05-06

Family

ID=10860081

Country Status (34)

Country Link
US (2) US20030158249A1 (sh)
EP (1) EP1214061B1 (sh)
JP (1) JP4866522B2 (sh)
KR (1) KR100670416B1 (sh)
CN (1) CN1174748C (sh)
AT (1) ATE269700T1 (sh)
AU (1) AU777583B2 (sh)
BG (1) BG65913B1 (sh)
BR (1) BR0013625A (sh)
CA (1) CA2382294C (sh)
CZ (1) CZ301378B6 (sh)
DE (1) DE60011794T2 (sh)
DK (1) DK1214061T3 (sh)
EA (1) EA004804B1 (sh)
EE (1) EE05124B1 (sh)
ES (1) ES2218223T3 (sh)
GB (1) GB9920548D0 (sh)
HK (1) HK1048944B (sh)
HR (1) HRP20020171A2 (sh)
HU (1) HU228861B1 (sh)
IL (2) IL147489A0 (sh)
ME (1) ME00624B (sh)
MX (1) MXPA02002041A (sh)
NO (1) NO328527B1 (sh)
NZ (1) NZ517604A (sh)
PL (1) PL212612B1 (sh)
PT (1) PT1214061E (sh)
RS (1) RS50148B (sh)
SI (1) SI1214061T1 (sh)
SK (1) SK286378B6 (sh)
TW (1) TW589180B (sh)
UA (1) UA72927C2 (sh)
WO (1) WO2001015675A2 (sh)
ZA (1) ZA200201408B (sh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
CN103054798B (zh) * 2005-08-31 2021-03-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
NZ592132A (en) * 2005-08-31 2012-12-21 Abraxis Bioscience Llc Composition comprising nanoparticles of docitaxel and a citrate
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
EP2146695A4 (en) * 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
PL2552438T3 (pl) 2010-03-26 2016-12-30 Sposoby leczenia raka wątrobowokomórkowego
CA2798180A1 (en) * 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
CA2275889C (en) * 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
AU1146099A (en) * 1997-09-18 1999-04-05 Janssen Pharmaceutica N.V. Fused imidazole derivatives for improving oral bioavailability of pharmaceuticalagents
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
CZ20012320A3 (cs) * 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
US8080672B2 (en) * 2005-12-13 2011-12-20 Teva Pharmaceutical Industries Ltd. Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
HUP0203197A3 (en) 2005-01-28
HK1048944A1 (en) 2003-04-25
NO20020829L (no) 2002-02-20
DE60011794T2 (de) 2005-07-14
CZ2002739A3 (cs) 2002-06-12
EA004804B1 (ru) 2004-08-26
NO328527B1 (no) 2010-03-08
ZA200201408B (en) 2003-07-30
IL147489A (en) 2006-06-11
GB9920548D0 (en) 1999-11-03
JP2003508427A (ja) 2003-03-04
MEP7809A (en) 2011-12-20
HRP20020171A2 (en) 2004-02-29
EA200200313A1 (ru) 2002-08-29
US20030158249A1 (en) 2003-08-21
MXPA02002041A (es) 2002-08-20
BG65913B1 (bg) 2010-05-31
WO2001015675A2 (en) 2001-03-08
DK1214061T3 (da) 2004-11-01
EP1214061A2 (en) 2002-06-19
CA2382294A1 (en) 2001-03-08
WO2001015675A3 (en) 2001-09-20
US20080045584A1 (en) 2008-02-21
ES2218223T3 (es) 2004-11-16
CN1372466A (zh) 2002-10-02
JP4866522B2 (ja) 2012-02-01
CA2382294C (en) 2008-06-03
EE05124B1 (et) 2009-02-16
EP1214061B1 (en) 2004-06-23
BG106460A (bg) 2002-09-30
CN1174748C (zh) 2004-11-10
HUP0203197A2 (hu) 2003-01-28
HK1048944B (zh) 2005-04-22
NZ517604A (en) 2004-04-30
TW589180B (en) 2004-06-01
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
PT1214061E (pt) 2004-09-30
KR20020060166A (ko) 2002-07-16
SK286378B6 (sk) 2008-08-05
PL212612B1 (pl) 2012-10-31
DE60011794D1 (de) 2004-07-29
RS50148B (sr) 2009-05-06
AU777583B2 (en) 2004-10-21
CZ301378B6 (cs) 2010-02-03
SI1214061T1 (en) 2004-12-31
ME00624B (me) 2011-12-20
SK2712002A3 (en) 2002-07-02
EE200200087A (et) 2003-04-15
KR100670416B1 (ko) 2007-01-17
UA72927C2 (uk) 2005-05-16
IL147489A0 (en) 2002-08-14
NO20020829D0 (no) 2002-02-20
PL353198A1 (en) 2003-11-03
HU228861B1 (hu) 2013-06-28
BR0013625A (pt) 2002-05-14

Similar Documents

Publication Publication Date Title
YU11402A (sh) Nova primena docetaksela za lečenje hepatoma
MY147643A (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
GB0223038D0 (en) Therapeutic compounds
MX349188B (es) Sns - 595 y metodos para utilizar el mismo.
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
GB0225474D0 (en) Therapeutic agents
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
DE60204966D1 (de) Verwendung von cyclopamine zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
PT1435991E (pt) Utilização de aplidina para o tratamento de cancro pancreático
SI1603584T1 (sl) Aplidin za zdravljenje multiple mieloma
ATE262362T1 (de) Verwendung von cyamemazin zur behandlung von entwöhnungserscheinungen der benzodiazepinbehandlung
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2008060535A3 (en) Use of reversine and analogs for treatment of cancer
UA32314A (uk) Спосіб лікування некротичного панкреатиту
UA95094C2 (ru) Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства
ATE319443T1 (de) Prävention oder behandlung von brust-, prostata- und/oder gebärmutterhalskrebs mit n,n- dimethylglycin